Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 372

Arterial Involvement in Erdheim-Chester Disease: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 355

Association of HLA-DRB1 Shared Epitope Alleles with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 369

Association of Retroperitoneal Fibrosis with Malignancy and the Pathologic Features of Malignancy with Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 359

Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Induced Arthritis

9:00AM-11:00AM: Abstract Number: 350

Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts

9:00AM-11:00AM: Abstract Number: 364

Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 362

Immune Check Point Inhibitors, Auto-Antibodies, and Immune Adverse Reactions

9:00AM-11:00AM: Abstract Number: 356

Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill

9:00AM-11:00AM: Abstract Number: 353

Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years

9:00AM-11:00AM: Abstract Number: 363

Immune-Related Adverse Events in Cancer Immunotherapy: How Often Do We See Them?

9:00AM-11:00AM: Abstract Number: 358

Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications

9:00AM-11:00AM: Abstract Number: 367

Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors

9:00AM-11:00AM: Abstract Number: 366

Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 365

Monoclonal Gammopathy in Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 357

Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia

9:00AM-11:00AM: Abstract Number: 352

Polymyalgia Rheumatica-like Syndrome from Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature

9:00AM-11:00AM: Abstract Number: 354

Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 351

Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy

9:00AM-11:00AM: Abstract Number: 361

Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab

9:00AM-11:00AM: Abstract Number: 370

Rituximab in Idiopathic Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 360

Sarcoidosis Induced By Immune Check Point Inhibitors

9:00AM-11:00AM: Abstract Number: 368

Synovianalysis Using Leukocyte Esterase Reagent Strips

9:00AM-11:00AM: Abstract Number: 371

Therapeutic Efficacy and Safety of Iguratimod in Treating Mild IgG4-Related Diseases

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].